ORIC Pharmaceuticals (ORIC) PT Raised to $15 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts ORIC Hot Sheet
Price: $9.34 --0%
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Rating Summary:
17 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 36 | New: 6
Join SI Premium – FREE
Oppenheimer analyst Matthew Biegler raised the price target on ORIC Pharmaceuticals (NASDAQ: ORIC) to $15.00 (from $12.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Freedom Broker Downgrades MasterCard (MA) to Hold
- Sony (SONY) PT Raised to $26 at Bernstein SocGen Group
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
